| Literature DB >> 21734881 |
H Shimosawa1, M Matsumoto, H Yabe, M Mukai, Y Toyama, H Morioka.
Abstract
Primary spinal primitive neuroectodermal tumors (PNETs) are very rare conditions. Most of these tumors occur in children and young adults. A 63-year-old man with a primary spinal PNET in the conus medullaris from the L1 to L2 level is presented in this report. The optimal treatment of primary spinal PNETs is yet unknown. Surgical resection, radiation therapy, and chemotherapy have been advocated for the treatment of spinal PNET based on PNETs at other sites. However, the outcome is very poor. There are a few reports of cases with long-term survival and no recurrence. In these patients, en bloc resections were performed.Entities:
Keywords: Conus medullaris; Elderly patient; Ewing's sarcoma family of tumors; Primitive neuroectodermal tumor
Year: 2011 PMID: 21734881 PMCID: PMC3124460 DOI: 10.1159/000323263
Source DB: PubMed Journal: Case Rep Oncol ISSN: 1662-6575
Fig. 1Spinal MRI showed a disc hernia at the L2-L3 level and a generally isointense intradural tumor with focal high-intensity T1-weighted images at the level of L1-L2 (a). On T2-weighted MRI, the tumor demonstrated high intensity with focal low intensity (b). The tumor is homogenously enhanced by gadolinium (c).
Fig. 2Histopathological examination of the tumor specimen revealed a highly cellular, poorly differentiated neoplasm. The tumor was composed of small round cells with scanty cytoplasm and hyperchromatic nuclei. No well-defined Homer Wright and only a few ependymal rosettes were found (a). Immunohistochemical staining for NSE was strongly positive (pictures not shown), as was staining for CD99 (MIC2) (b).
Fig. 3Spinal MRI demonstrated an intraspinal tumor extending from the Th12 to L2 level. The tumor showed high intensity on T1-weighted image (a) as well as on T2-weighted image (b).
Fig. 4Protocol of chemotherapy. RT-1 = Local radiation 16 Gy; RT-2 = radiation to brain and spinal cord 14 Gy; VDC = vincristine (1.5 mg/m2) + doxorubicin (30 mg/m2) + cyclophosphamide (1,200 mg/m2); IE = ifosfamide (1.8 g/m2) + etoposide (100 mg/m2).
Fig. 5MRI after chemotherapy and radiation. a T1-weighted image. b T2-weighted image. T1-weighted image with gadolinium enhancement.
Summary of patients with a primary spinal PNET
| Patient [ref.] | Age | Sex | Site | Survival period | Recurrence and metastasis |
|---|---|---|---|---|---|
| 1 [ | 24 years | M | lumbar, cauda equina | 10 months | lung |
| 2 [ | 6 months to 10 years | NA | cervical | NA | NA |
| 3 [ | 6 months to 10 years | NA | cervical | NA | NA |
| 4 [ | 6 months to 10 years | NA | thoracic-lumbar | NA | NA |
| 5 [ | 24 years | M | lumbar, intradural, cauda equina | 18 months | local recurrence |
| 6 [ | 56 years | M | lumbar, intradural, cauda equina | alive at 36 month | none |
| 7 [ | 39 years | M | lumbar, intradural, cauda equina | 30 months | local recurrence |
| 8 [ | 26 years | M | cervical, intradural, extramedullary | 10 days | spinal canal, diffuse bone |
| 9 [ | 26 years | F | lumbar-sacral, extradural | alive at 6 months | none |
| 10 [ | 26 years | M | thoracic-lumbar, intramedullary | 36 months | between two frontal horns, roof 4th ventricle |
| 11 [ | 15 years | F | thoracic-lumbar, intra- and extramedullary | 18 months | local recurrence |
| 12 [ | 7 years | M | thoracic-sacral, intramedullary | 20 months | local progression to cervical |
| 13 [ | 16 years | F | lumbar, intramedullary | 29 months | brain |
| 14 [ | 47 years | M | lumbar-sacral, cauda equina, intra- and extramedullary | 16 months | local progression |
| 15 [ | 3 months | F | thoracic-lumbar, intramedullary | 15 days | brain |
| 16 [ | 22 years | F | thoracic-lumbar, intramedullary | alive at 15 months | local recurrence |
| 17 [ | 23 years | F | thoracic, intradural extramedullary | alive at 12 months | none |
| 18 [ | 32 years | M | sacral, cauda equina | 29 months | local progression, brain |
| 19 [ | 17 years | M | lumbar, cauda equina | alive at 23 months | none |
| 20 [ | 52 years | M | lumbar-sacral, cauda equina | alive at 12 months | none |
| 21 [ | 5 years | M | thoracic, extradural | alive at 8 months | none |
| 22 [ | 69 years | M | cervical-thoracic, intra- and extramedullary | 3 months | none |
| 23 [ | 22 years | F | thoracic, extramedullary | alive at 9 months | local recurrence, brain |
| 24 [ | 49 years | F | lumbar, cauda equina | 23 months | diffuse intraspinal progression |
| 25 [ | 29 years | F | thoracic, intramedullary | 17 months | multiple intraspinal |
| 26 [ | 26 years | M | cervical, intrameningeal | 3 months | local recurrence, diffuse intraspinal |
| 27 [ | 12 years | F | cervical-thoracic, extradural | 32 months | local recurrence |
| 28 [ | 10 years | M | cervical-thoracic, extradural | 22 months | multiple lung |
| 29 [ | 30 years | F | cervical, extramedullary | 14 months | local recurrence |
| 30 [ | 14 years | M | lumbar, extramedullary | alive at 67 months | none |
| 31 [ | 31 years | F | lumbar-sacral, cauda equina | 2 months | local recurrence, left frontoparietal |
| 32 [ | 3 years | M | cervical, intramedullary | several days | local progression to brainstem |
| 33 [ | 38 years | M | thoracic, intramedullary | 18 months | brain, multiple spinal cord |
| 34 [ | 54 years | F | cervical, intramedullary | NA | none |
| 35 [ | 9 years | F | thoracic-lumbar, extramedullary | alive at 18 months | none |
| 36 [ | 8 years | M | cervical, extradural | alive at 8 months | local recurrence |
| 37 [ | 18 years | M | cervical, intramedullary | alive at 6 months | none |
| 38 [ | 17 years | M | thoracic, intramedullary | alive at 6 months | none |
NA = Not available.